FLT3 and acute myeloid leukemia: Indeed, it has been extensively described how MSCs endow AML cells with resistance to several therapeutic agents, including standard chemotherapy and new molecular targeted agents such as Fms-like tyrosine kinase (FLT3) inhibitors (midostaurin, sorafenib, and quizartinib).